Skip to content

Clinical trials

Kidney Neoplasms trials with no applicable phase and unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Kidney Neoplasms Phase: Not applicable Status: Unknown status Clear all

31 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20052
20071
20092
20122
20131
20142
20162
20174
20182
20191
20202
20213
20223
20232
20242

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status31

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
I.M. Sechenov First Moscow State Medical University2
Tokushukai Medical Group2
University Hospital, Grenoble2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1
Assistance Publique Hopitaux De Marseille1
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia1
Cedars-Sinai Medical Center1
Centre Hospitalier Universitaire de Besancon1
Children's Cancer and Leukaemia Group1
First Affiliated Hospital, Sun Yat-Sen University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Kidney Neoplasms31
Carcinoma, Renal Cell10
Prostatic Neoplasms4
Lymphoma3
Renal Insufficiency3
Urinary Bladder Neoplasms3
Dendritic Cell Sarcoma, Interdigitating2
Leukemia2
Precursor Cell Lymphoblastic Leukemia-Lymphoma2
Rectal Neoplasms2

Trials

Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.